MCID: THY025
MIFTS: 57

Thymus Cancer

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Thymus Cancer

MalaCards integrated aliases for Thymus Cancer:

Name: Thymus Cancer 11 41 14
Malignant Neoplasm of Thymus 71 31
Thymus Neoplasms 43 71
Thymus Neoplasm 75 16
Thymic Tumor 11 58
Primary Malignant Neoplasm of Thymus 33
Malignant Tumour of Thymus 33
Thymic Glandular Cancer 33
Thymus Gland Cancer 33
Neoplasm of Thymus 11
Thymoma, Familial 71
Thymic Carcinoma 71
Thymic Neoplasms 53
Cancer of Thymus 33
Thymic Neoplasm 11
Thymoma, Type C 71

Classifications:



Summaries for Thymus Cancer

MedlinePlus: 41 The thymus is a small organ in your upper chest, under your breastbone. Before birth and during childhood, the thymus helps the body make a type of white blood cell. These cells help protect you from infections. Cancer of the thymus is rare. You are more likely to get it if you have other diseases such as myasthenia gravis, lupus or rheumatoid arthritis. Sometimes there are no symptoms. Other times, thymus cancer can cause: A cough that doesn't go away Chest pain Trouble breathing Doctors use a physical exam, imaging tests, and a biopsy to diagnose thymus cancer. The most common treatment is surgery to remove the tumor. Other options include radiation therapy, chemotherapy, and hormone therapy. NIH: National Cancer Institute

MalaCards based summary: Thymus Cancer, also known as malignant neoplasm of thymus, is related to good syndrome and thymic carcinoma. An important gene associated with Thymus Cancer is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are CD28 co-stimulation and Hematopoietic Stem Cells and Lineage-specific Markers. The drugs Pembrolizumab and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include thymus, lung and thyroid, and related phenotypes are neoplasm of the thymus and immunodeficiency

Disease Ontology: 11 An immune system cancer located in the thymus.

Wikipedia: 75 A thymoma is a tumor originating from the epithelial cells of the thymus that is considered a rare... more...

Related Diseases for Thymus Cancer

Diseases related to Thymus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 643)
# Related Disease Score Top Affiliating Genes
1 good syndrome 32.3 CD8A CD4 CD274
2 thymic carcinoma 32.1 NKX2-1 KRT7 KIT CNTNAP2 CD5 CD274
3 thymoma 31.8 TTN NKX2-1 KRT7 KIT DPYSL5 CD8A
4 castleman disease 30.5 H2AC18 CD4 CCR6
5 thymus large cell carcinoma 30.5 KRT7 KIT CD5
6 cryptogenic organizing pneumonia 30.5 CD8A CD4 CD274
7 pure red-cell aplasia 30.4 CD8A CD4 AIRE
8 teratoma 30.4 NKX2-1 KRT7 KIT AKT1
9 lymphoepithelioma-like carcinoma 30.4 KRT7 KIT CD8A CD274
10 cortical thymoma 30.4 TTN AIRE
11 epithelial malignant thymoma 30.4 TTN CD5 AIRE
12 t-cell large granular lymphocyte leukemia 30.4 CD8A CD5 CD4
13 crescentic glomerulonephritis 30.4 ICOSLG CD8A CD4 CCR6
14 myasthenia gravis 30.4 TTN MUSK LRP4 AIRE
15 mediastinal cancer 30.3 NKX2-1 KRT7 KIT CD5
16 hemangioma 30.3 NKX2-1 KRT7 KIT AKT1
17 neuroendocrine carcinoma 30.3 NKX2-1 KRT7 KIT
18 lymphoma, mucosa-associated lymphoid type 30.3 ICOSLG CD5 CD4 CCR6
19 respiratory failure 30.3 TTN NKX2-1 MUSK H2AC18 CD8A CD4
20 pancreatic ductal adenocarcinoma 30.2 MIR205 MIR125A ICOSLG H2AC18 CCR6
21 myopathy 30.2 TTN ICOSLG H2AC18 CD8A CD4 CCR6
22 autoimmune disease 30.1 TTN MUSK ICOSLG CD5 CD274 CCR6
23 deficiency anemia 30.1 KIT ICOSLG H2AC18 CD8A CD5 CD4
24 thymus lymphoma 11.0
25 hilar lung neoplasm 10.5 CD8A CD4
26 proliferative glomerulonephritis 10.5 ICOSLG H2AC18 CCR6
27 lung carcinoma in situ 10.5 NKX2-1 KRT7 AKT1
28 lymphangitis 10.5 NKX2-1 KRT7 CD4
29 serous cystadenocarcinoma 10.5 KRT7 H2AC18 AKT1
30 ureter adenocarcinoma 10.5 NKX2-1 KRT7
31 gastroduodenitis 10.5 CD8A CD4 CCR6
32 laryngeal adenoid cystic carcinoma 10.5 KRT7 KIT
33 third ventricle chordoid glioma 10.5 NKX2-1 CD4
34 mucinous bronchioloalveolar adenocarcinoma 10.5 NKX2-1 KRT7
35 skin sarcoidosis 10.5 CD8A CD4 CCR6
36 syphilis 10.5 CD8A CD4 CCR6
37 ureter small cell carcinoma 10.5 NKX2-1 KRT7 KIT
38 invasive malignant thymoma 10.5 MUSK CD8A CD4
39 mikulicz disease 10.5 ICOSLG CD4 CCR6
40 autoimmune cholangitis 10.5 CD8A CD4 CCR6
41 farmer's lung 10.5 CD8A CD4 CCR6
42 oral tuberculosis 10.5 CD8A CD4
43 thymus clear cell carcinoma 10.5 NKX2-1 KIT CD5
44 follicular mucinosis 10.5 CD8A CD5 CD4
45 evans' syndrome 10.5 CD8A CD4 CCR6
46 basaloid squamous cell carcinoma 10.5 NKX2-1 KRT7 KIT
47 early yaws 10.5 CD8A CD4
48 parapsoriasis 10.5 CD8A CD5 CD4
49 thymus basaloid carcinoma 10.5 NKX2-1 CD5
50 primary cutaneous gamma-delta t-cell lymphoma 10.5 CD8A CD5 CD4

Graphical network of the top 20 diseases related to Thymus Cancer:



Diseases related to Thymus Cancer

Symptoms & Phenotypes for Thymus Cancer

Human phenotypes related to Thymus Cancer:

58 30 (show all 21)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the thymus 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100521
2 immunodeficiency 58 30 Frequent (33%) Frequent (79-30%)
HP:0002721
3 palpebral edema 58 30 Frequent (33%) Frequent (79-30%)
HP:0100540
4 dyspnea 58 30 Frequent (33%) Frequent (79-30%)
HP:0002094
5 cough 58 30 Frequent (33%) Frequent (79-30%)
HP:0012735
6 chest pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0100749
7 mediastinal lymphadenopathy 58 30 Frequent (33%) Frequent (79-30%)
HP:0100721
8 diaphragmatic paralysis 58 30 Frequent (33%) Frequent (79-30%)
HP:0006597
9 dysgammaglobulinemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002961
10 ptosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000508
11 dysphagia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002015
12 increased intracranial pressure 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002516
13 autoimmunity 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002960
14 pericarditis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001701
15 headache 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002315
16 abnormal bleeding 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001892
17 fatigable weakness 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003473
18 cardiac arrest 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001695
19 language impairment 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002463
20 neuroendocrine neoplasm 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100634
21 edema 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Thymus Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.73 AIRE AKT1 CCR6 CD4 CD8A CNTNAP2
2 no phenotypic analysis MP:0003012 9.7 AIRE CD274 CD4 CD5 KIT MIR205
3 integument MP:0010771 9.32 AKT1 CD274 CD4 CD5 CD8A KIT

Drugs & Therapeutics for Thymus Cancer

Drugs for Thymus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pembrolizumab Approved Phase 4 1374853-91-4 254741536
2
Etoposide Approved Phase 3 33419-42-0 36462
3
Etoposide phosphate Phase 3 16760419
4
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286
5
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
6
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
7
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
8
Pasireotide Approved Phase 2 396091-73-9 56841596 9941444
9
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
10
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
11
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605 16129706
12
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
13
Busulfan Approved, Investigational Phase 2 55-98-1 2478
14
Melphalan Approved Phase 2 148-82-3 4053 460612
15
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
16
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
17
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
18
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
19
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
20
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
21
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
22
Avelumab Approved, Investigational Phase 2 1537032-82-8
23
Ramucirumab Approved, Investigational Phase 2 947687-13-0
24
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
25
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
26
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
27
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
28
Nedaplatin Approved, Investigational Phase 2 95734-82-0
29
Cetuximab Approved Phase 2 205923-56-4
30
Nivolumab Approved Phase 1, Phase 2 946414-94-4
31
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
32
Sargramostim Approved, Investigational Phase 2 123774-72-1
33
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
34
Plicamycin Approved, Investigational, Withdrawn Phase 1, Phase 2 18378-89-7 163659 52945526
35
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
36
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
37
Belinostat Approved, Investigational Phase 1, Phase 2 414864-00-9, 866323-14-0 53437714 6918638
38
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
39
Doxepin Approved, Investigational Phase 2 1668-19-5 667468 667477
40
Histamine Approved, Investigational Phase 2 51-45-6 774
41
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
42
Promethazine Approved, Investigational Phase 2 60-87-7 4927
43
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
44
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
45
Amrubicin Investigational Phase 2 110267-81-7 13502539 3035016
46
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7 4897
47
Lexatumumab Investigational Phase 2 845816-02-6
48
Vorolanib Investigational Phase 1, Phase 2 1013920-15-4
49
Molgramostim Investigational Phase 2 99283-10-0
50
Saracatinib Investigational Phase 2 379231-04-6 10302451

Interventional clinical trials:

(show top 50) (show all 98)
# Name Status NCT ID Phase Drugs
1 Single-Arm Study to Carbo-paclitaxel/ Nab-paclitaxel Combined With Pembrolizumab as the First Line Therapy in Treating Patients With Locally Advanced or Metastatic Invasive Thymoma and Thymic Carcinoma That Cannot Be Removed by Surgery Recruiting NCT04554524 Phase 4 Chemotherapy+Pembrolizumab.
2 A Multi-institutional, Randomized Controlled Trial of Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Unknown status NCT02014805 Phase 3
3 An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection Recruiting NCT02633553 Phase 3
4 A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
5 Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas Unknown status NCT02364076 Phase 2 Pembrolizumab;Epacadostat
6 Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort Unknown status NCT03921671 Phase 2
7 Samsung Medical Center Unknown status NCT03219554 Phase 2 Palbociclib
8 A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy. Unknown status NCT03466827 Phase 2 Selinexor
9 A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Completed NCT01364727 Phase 2 Amrubicin
10 An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND Completed NCT02307500 Phase 2 Regorafenib
11 A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy Completed NCT02607631 Phase 2 Pembrolizumab
12 Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Completed NCT02049047 Phase 2 Everolimus
13 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
14 Phase II Study of Trimodality Therapy for Patients With Thymoma or Thymic Carcinoma at Significant Risk for Recurrence Completed NCT00387868 Phase 2 cisplatin and etoposide
15 A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
16 A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin Completed NCT02420691 Phase 2 Ribociclib
17 A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma Completed NCT00589290 Phase 2 Belinostat (PDX101)
18 Radiofrequency Ablation of Pulmonary Malignancy Completed NCT00024076 Phase 2
19 Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
20 Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study Completed NCT00990535 Phase 2 Octreotide-LAR
21 Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size Completed NCT00332969 Phase 2 Octreotide
22 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
23 Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
24 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
25 A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
26 Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies Completed NCT01163552 Phase 2
27 A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Completed NCT02220855 Phase 2 BKM120
28 A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
29 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
30 A Phase II, Neo-adjuvant Pembrolizumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Pembrolizumab Consolidation Therapy in Locally Advanced Thymic Epithelial Tumor (TET) Recruiting NCT03858582 Phase 2 pembrolizumab
31 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
32 Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Recruiting NCT03134118 Phase 2 Nivolumab
33 A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma Recruiting NCT04417660 Phase 2 M7824
34 A Phase II, Open-Label Trial of PT-112 in Subjects With Thymoma and Thymic Carcinoma Recruiting NCT05104736 Phase 2 PT-112
35 Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
36 A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma Recruiting NCT03694002 Phase 2 Carboplatin;Paclitaxel
37 An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma Recruiting NCT04321330 Phase 2 Atezolizumab
38 A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI. Recruiting NCT04710628 Phase 2 Pembrolizumab;Lenvatinib 10 mg
39 A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma Recruiting NCT04469725 Phase 2 KN046
40 Phase II Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors Recruiting NCT04925947 Phase 2 KN046
41 A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma Recruiting NCT03463460 Phase 2 Sunitinib Malate
42 A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy Active, not recruiting NCT01621568 Phase 2 Sunitinib
43 Hypofractionated Radiotherapy Combined With Concurrent Weekly Chemotherapy and Thymosin α1 in Patients With Unresectable or Recurrent Thymic Epithelial Tumor: A Prospective, Single-arm Phase II Study Active, not recruiting NCT03663764 Phase 2 Thymosin a1;concurrent chemoradiotherapy
44 A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007) Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
45 Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors Active, not recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
46 Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor Not yet recruiting NCT04667793 Phase 2 Toripalimab;Chemotherapy
47 Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors Not yet recruiting NCT04517539 Phase 2 rhGM-CSF,Peginterferon alfa-b2,radiation
48 Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Terminated NCT02859415 Phase 1, Phase 2 Mithramycin
49 Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma) Terminated NCT00718809 Phase 2 saracatinib
50 A Phase II Study of Paclitaxel and Cisplatin in Previously Untreated, Unresectable Invasive Thymoma or Thymic Carcinoma Terminated NCT00818090 Phase 2 paclitaxel and cisplatin

Search NIH Clinical Center for Thymus Cancer

Cochrane evidence based reviews: thymus neoplasms

Genetic Tests for Thymus Cancer

Anatomical Context for Thymus Cancer

Organs/tissues related to Thymus Cancer:

FMA: Thymus
MalaCards : Thymus, Lung, Thyroid, T Cells, B Cells, Bone Marrow, Liver

Publications for Thymus Cancer

Articles related to Thymus Cancer:

(show top 50) (show all 493)
# Title Authors PMID Year
1
CD59 Expression in Skeletal Muscles and Its Role in Myasthenia Gravis. 41
36396448 2023
2
Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis. 41
36450378 2022
3
Prognostic value of tumor size in thymic epithelial tumors: A systematic review and meta-analysis. 41
36401408 2022
4
Utility of immunohistochemistry in separating thymic neoplasms from germ cell tumors and metastatic lung cancer involving the anterior mediastinum. 53 62
12777991 2003
5
Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms. 53 62
11952859 2002
6
Incidental Detection of a Type B3 Thymoma on 68Ga-FAPI-04 PET/CT Imaging. 62
36469078 2023
7
Thymic lipofibroadenoma of the anterior mediastinum: A rare case report. 62
36401401 2022
8
Approach to Mediastinal Fine Needle Aspiration Cytology. 62
35838636 2022
9
LCK-Mediated RIPK3 Activation Controls Double-Positive Thymocyte Proliferation and Restrains Thymic Lymphoma by Regulating the PP2A-ERK Axis. 62
36161785 2022
10
Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report. 62
36401466 2022
11
Rare case of an exceedingly enlarged mediastinal mass in 22-year-old male. 62
36324768 2022
12
Added Value of Magnetic Resonance Over Computed Tomography in Distinguishing Nonneoplastic Complex Thymic Cysts From Malignant Cystic Thymic Neoplasms. 62
36103678 2022
13
Modified subcostal arch xiphoid thoracoscopic expanded thymectomy for thymic carcinoma: a case report and review of literature. 62
36088333 2022
14
Early development of pembrolizumab-induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma. 62
36034177 2022
15
Early Detection of Relapse by ctDNA Sequencing in a Patient with Metastatic Thymic Tumor and MEN1 Mosaicism. 62
35904487 2022
16
Lifetime Exposure to Welding Fumes and Risk of Some Rare Cancers. 62
35872594 2022
17
Thymoma (World Health Organization Type AB) in multiple endocrine neoplasia type 1: a case report. 62
35821790 2022
18
Pretracheal ectopic thymoma: A diagnostic challenge in endobronchial ultrasound-guided transbronchial needle aspiration cytology. 62
35445470 2022
19
Management of incidentally detected small anterior mediastinal nodules: Which way to go? 62
35462112 2022
20
Ectopic adrenocorticotrophic hormone syndrome initially presenting as abnormal mental behavior caused by thymic carcinoid: a case report. 62
35531113 2022
21
COMPARATIVE ANALYSIS OF CURRENT SURGICAL APPROACHES TO THYMIC TUMORS TREATMENT. 62
35417859 2022
22
[Mediastinal lesions : The most common pathologies in chest X-rays and their correlations in computed tomography]. 62
35024887 2022
23
Differentiating thymoma, thymic carcinoma and lymphoma based on collagen fibre patterns with T2- and diffusion-weighted magnetic resonance imaging. 62
34215941 2022
24
Factors predicting perioperative outcomes in patients with myasthenia gravis or thymic neoplasms undergoing thymectomy by video-assisted thoracoscopic approach. 62
35017401 2022
25
Surgical management of locally advanced thymic neoplasms. 62
35340838 2022
26
Current Roles of PET/CT in Thymic Epithelial Tumours: Which Evidences and Which Prospects? A Pictorial Review. 62
34885200 2021
27
Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases. 62
34944522 2021
28
Regression of thymoma-induced lichenoid hypersensitivity reactions of the oral mucosa following thymoma treatment: a case report. 62
34678738 2021
29
Viral infection in thymoma and thymic tumors with autoimmune diseases. 62
34532982 2021
30
A Rare Thymic Tumor - Lipofibroadenoma - Always a Postoperative Surprise. 62
34697204 2021
31
Thymic tumours: a single center surgical experience and literature review on the current diagnosis and management of thymic malignancies. 62
34926228 2021
32
Surgical management of locally invasive basaloid carcinoma of thymic gland. 62
34858582 2021
33
Lymph Nodes Involvement and Lymphadenectomy in Thymic Tumors: Tentative Answers for Unsolved Questions. 62
34680234 2021
34
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus. 62
34515662 2021
35
Thymolipoma and its Association with Myasthenia Gravis: a Multi-center Experience. 62
35169361 2021
36
Role of modern neoadjuvant chemoradiotherapy in locally advanced thymic epithelial neoplasms. 62
33174515 2021
37
Diffuse panbronchiolitis as parathymic syndrome in a Caucasian man previously treated for thymoma. 62
34408804 2021
38
Thymic Carcinoma With Multiple Paraneoplastic Disorders. 62
33961845 2021
39
Tumor immunity is related to 18 F-FDG uptake in thymic epithelial tumor. 62
34363337 2021
40
Recurrent anti-AMPA receptor encephalitis associated with thymus cancer. 62
33939040 2021
41
Micronodular Thymoma with Lymphoid Stroma: A Case Report. 62
34216482 2021
42
Development of thymic tumor in [LSL:KrasG12D; Pdx1-CRE] mice, an adverse effect associated with accelerated pancreatic carcinogenesis. 62
34302028 2021
43
Urgent lung transplantation for thymic neoplasm-associated severe constrictive bronchiolitis with bronchiectasis and radiotherapy-induced organizing pneumonia: A case report. 62
33830653 2021
44
Dual-scopic robotic thymectomy for a large thymic malignant tumor. 62
34221347 2021
45
De novo hepatocellular carcinoma in a non-cirrhotic allograft 27 years after liver transplantation: A case report. 62
33382179 2021
46
Thymic Metastasis of Ovarian Cancer 33 Years After Primary Surgery. 62
33130116 2021
47
Apoptosis inducing properties of 3-biotinylate-6-benzimidazole B-nor-cholesterol analogues. 62
33722574 2021
48
[Chinese guideline for clinical diagnosis and treatment of thymic epithelial tumors (2021 Edition)]. 62
33902202 2021
49
Prosthetic Reconstruction of Superior Vena Cava System for Thymic Tumor: A Retrospective Analysis of 22 Cases. 62
32005044 2021
50
Comparison of Subxiphoid and Intercostal Uniportal Thoracoscopic Thymectomy for Nonmyasthenic Early-Stage Thymoma: A Retrospective Single-Center Propensity-Score Matching Analysis. 62
32886931 2021

Variations for Thymus Cancer

Cosmic variations for Thymus Cancer:

8 (show all 36)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM105695698 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 13
2 COSM142891951 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 13
3 COSM87975416 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 13
4 COSM142627127 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 13
5 COSM121944830 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-21T>A p.? 17:7675236-7675236 13
6 COSM106116533 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 13
7 COSM144072853 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.343T>A p.Y115N 17:7675236-7675236 13
8 COSM144363948 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 13
9 COSM122332176 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-21T>A p.? 17:7675236-7675236 13
10 COSM93250189 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 13
11 COSM145076506 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 13
12 COSM122804157 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-21T>A p.? 17:7675236-7675236 13
13 COSM144718880 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 13
14 COSM144140974 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-102T>A p.? 17:7675236-7675236 13
15 COSM112319052 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 13
16 COSM143214478 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-102T>A p.? 17:7675236-7675236 13
17 COSM143433019 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 13
18 COSM111826108 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 13
19 COSM144005441 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-102T>A p.? 17:7675236-7675236 13
20 COSM103083119 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 18:51065548-51065548 13
21 COSM139771670 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.793C>T p.R265C 18:51065548-51065548 13
22 COSM91380576 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 18:51065548-51065548 13
23 COSM88596522 PREX2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.107G>T p.R36L 8:67952501-67952501 13
24 COSM88408638 NOTCH2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3359G>A p.C1120Y 1:119937445-119937445 13
25 COSM87667907 KMT2D thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12634C>T p.R4212W 12:49032071-49032071 13
26 COSM88314740 KIT thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1657T>A p.Y553N 4:54727425-54727425 13
27 COSM132270273 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2768C>T p.A923V 23:45078488-45078488 13
28 COSM101719617 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2870C>T p.A957V 23:45078488-45078488 13
29 COSM145420036 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.*1915C>T p.? 23:45078488-45078488 13
30 COSM143359668 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3005C>T p.A1002V 23:45078488-45078488 13
31 COSM102181889 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2921C>T p.A974V 23:45078488-45078488 13
32 COSM132025397 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2714C>T p.A905V 23:45078488-45078488 13
33 COSM85170206 IL7R thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 5:35871214-35871214 13
34 COSM121730466 IL7R thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 5:35871214-35871214 13
35 COSM143857324 FAT1 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12712A>G p.K4238E 4:186596834-186596834 13
36 COSM110448949 FAT1 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12706A>G p.K4236E 4:186596834-186596834 13

Expression for Thymus Cancer

Search GEO for disease gene expression data for Thymus Cancer.

Pathways for Thymus Cancer

GO Terms for Thymus Cancer

Cellular components related to Thymus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.47 KIT ICOSLG CD8A CD5 CD4 CD274

Biological processes related to Thymus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.76 MUSK KIT CD8A CD4
2 T cell costimulation GO:0031295 9.43 CD5 CD274 AKT1
3 positive regulation of gene expression GO:0010628 9.36 TTN NKX2-1 MUSK MIR205 MIR125A KIT

Sources for Thymus Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....